A detailed history of Steward Partners Investment Advisory, LLC transactions in Bio N Tech Se stock. As of the latest transaction made, Steward Partners Investment Advisory, LLC holds 375 shares of BNTX stock, worth $45,270. This represents 0.0% of its overall portfolio holdings.

Number of Shares
375
Previous 275 36.36%
Holding current value
$45,270
Previous $22,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$78.36 - $124.66 $7,836 - $12,466
100 Added 36.36%
375 $44,000
Q4 2023

Feb 12, 2024

SELL
$90.91 - $112.75 $50,000 - $62,012
-550 Reduced 66.67%
275 $29,000
Q2 2023

Aug 14, 2023

SELL
$102.58 - $129.66 $7,078 - $8,946
-69 Reduced 7.72%
825 $89,000
Q1 2023

May 15, 2023

SELL
$122.57 - $153.67 $15,321 - $19,208
-125 Reduced 12.27%
894 $111,000
Q3 2022

Nov 10, 2022

SELL
$127.65 - $183.11 $2,425 - $3,479
-19 Reduced 1.83%
1,019 $137,000
Q2 2022

Aug 04, 2022

SELL
$123.25 - $186.24 $110,925 - $167,616
-900 Reduced 46.44%
1,038 $155,000
Q4 2021

Feb 08, 2022

BUY
$216.64 - $362.52 $14,948 - $25,013
69 Added 3.69%
1,938 $500,000
Q3 2021

Nov 12, 2021

SELL
$205.93 - $447.23 $43,451 - $94,365
-211 Reduced 10.14%
1,869 $510,000
Q2 2021

Aug 13, 2021

SELL
$113.32 - $241.49 $52,127 - $111,085
-460 Reduced 18.11%
2,080 $466,000
Q1 2021

May 14, 2021

BUY
$85.73 - $119.5 $144,883 - $201,955
1,690 Added 198.82%
2,540 $277,000
Q4 2020

Feb 11, 2021

BUY
$72.71 - $129.54 $50,896 - $90,678
700 Added 466.67%
850 $69,000
Q3 2020

Oct 30, 2020

BUY
$57.81 - $104.17 $2,890 - $5,208
50 Added 50.0%
150 $10,000
Q2 2020

Aug 06, 2020

BUY
$38.58 - $66.74 $3,858 - $6,673
100 New
100 $7,000

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $29.3B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Steward Partners Investment Advisory, LLC Portfolio

Follow Steward Partners Investment Advisory, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Steward Partners Investment Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Steward Partners Investment Advisory, LLC with notifications on news.